camizestrant
Sponsor Astrazeneca PLC · listed as AZN
camizestrant is a drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Apr 20, 2027 (day precision, medium confidence), tied to trial NCT05774951. That trial is in Phase 3 and currently recruiting, studying Breast Cancer, Early Breast Cancer. It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Other tracked assets in the same trials — NCT06380751: saruparib.
Trials for camizestrant in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT04964934 | Phase 3 | Active, not recruiting | 2025-06-30 | Experimental | AstraZeneca | ER-Positive HER2-Negative Breast Cancer |
| NCT04711252 | Phase 3 | Active, not recruiting | 2026-06-26 | Experimental | AstraZeneca | ER-Positive HER2-Negative Breast Cancer |
| NCT05774951 catalyst | Phase 3 | Recruiting | 2027-04-20 | Experimental | AstraZeneca | Breast Cancer, Early Breast Cancer |
| NCT07647328 | Phase 3 | Recruiting | 2029-02-28 | Experimental | AstraZeneca | ER-Positive HER2-Negative Breast Cancer |
| NCT06380751 | Phase 3 | Recruiting | 2029-12-18 | Experimental | AstraZeneca | Advanced Breast Cancer |
| NCT05952557 | Phase 3 | Active, not recruiting | 2030-03-04 | Experimental | AstraZeneca | Breast Cancer, Early Breast Cancer |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AZN catalysts